



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	396036	ProbioSpore
ARTG entry for	Medicine Listed	
Sponsor	Designs For Health Pty Ltd	
Postal Address	1 / 418 Pittwater Road, North Manly, NSW, 2100 Australia	
ARTG Start Date	16/09/2022	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . ProbioSpore

Product Type	Single Medicine Product	Effective Date	17/09/2024
---------------------	-------------------------	-----------------------	------------

Permitted Indications

Enhance/improve/promote/increase bowel regularity
Relief of symptoms of medically diagnosed Irritable Bowel Syndrome
Maintain/support healthy digestion
Maintain/support intestinal good/beneficial/friendly flora
Maintain/support gastrointestinal system health

Indication Requirements

Label statement for stimulant laxatives: Prolonged use may cause serious bowel problems.
Product presentation must not refer to or imply weight loss.
Label statement: If symptoms persist or worsen talk to your medical practitioner.
Product presentation must only refer to medically diagnosed IBS.
Label statement: Drink plenty of water (or words to that effect).
Label statement: Do not use when abdominal pain, nausea or vomiting are present or if you develop diarrhoea. If you are pregnant or breastfeeding - seek the advice of a healthcare professional before taking this product (or words to that effect).
Label statement: If symptoms persist, talk to your health professional.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Not suitable for children.
Bacillus coagulans may affect the way some medicines work, including immunosuppressants. Consult your health professional before taking with other medicines (or words to that effect)

Additional Product information



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Pack Size/Poison information	
Pack Size	Poison Schedule
Components	
1 . Formulation 1	
Dosage Form	Capsule, hard
Route of Administration	Oral
Visual Identification	
Active Ingredients	
Bacillus coagulans	4 billion CFU
Other Ingredients (Excipients)	
colloidal anhydrous silica	
magnesium stearate	
maltodextrin	
microcrystalline cellulose	

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary